Biotech Co.* (Country; Symbol)

Pharma Co. (Country)

Type/Product Area

Terms/Details (Date)

Accelrys Inc. (subsidiary of Pharmacopeia Inc.; ACCL)

Henkel KGaA (Germany)

Three-year license deal under which Henkel will use Accelrys' Materials Studio software

The deal builds on a relationship in which Henkel was a member of Accelrys' Formulations Consortium to develop software solutions; terms were not disclosed (3/9)

Advancis Pharmaceutical Corp. (AVNC)

Par Pharmaceuticals Inc.

Companies signed a letter of intent to develop Advancis' Amoxicillin Pulsys

Par would pay $5M up front and fund further development in exchange for co-marketing rights; they would share marketing expenses and revenues, and Advancis would manufacture the product (3/2)

Affymetrix Inc. (AFFX)

Aventis SA (France)

Agreement that provides Aventis early access to the GeneChip High-Throughput Array

Terms of the deal were not disclosed (3/3)

Alliance Pharmaceutical Corp. (OTC BB:ALLP)

Nycomed Danmark ApS (Denmark)

Nycomed will develop and commercialize the snythetic oxygen carrier Oxygent in Europe

Nycomed also gained an option to rights in China; Alliance would get a royalty on sales; further terms were not disclosed (4/5)

Amphora Discovery Corp.*

Aventis SA (France)

Two-year deal for lead generation across Aventis' global research sites; Amphora will identify small-molecule kinase inhibitors for multiple targets

Amphora gets research funding and potential milestones and royalties; Aventis has an option to extend the deal (3/30)

Anadys Pharmaceuticals Inc. (ANDS)

LG Life Sciences Ltd. (South Korea) B infection

Anadys acquired exclusive rights to LB80380 (ANA380) for treating chronic hepatitis

The rights include most of the world, including Japan but excluding certain other countries in Asia; they will jointly fund global development; specific terms were not disclosed (4/19)

AnorMed Inc. (Canada; TSE:AOM)

Shire Pharmaceuticals Group plc (UK)

AnorMed is selling Shire the global patents for Fosrenol

Shire would pay $18M when the product is approved in the U.S. and $7M when approved in Europe; Shire's royalty obligations ended except in Japan, where it has an option to purchase patents for $6M (3/23)

Antigenics Inc. (AGEN)

Virbac SA (France)

Antigenics sold its manufacturing rights for feline leukemia virus vaccine

Virbac, which has had exclusive marketing rights to the product since 1983, paid $14.25M in cash for all remaining rights (3/18)

Antisoma plc (UK; LSE:ASM)

Inverness Medical Innovations Inc.

Antisoma acquired certain royalty rights to products based on mouse and humanized variants of the antibody HMFG1, on which the producs R1549 and R1550 are based

The drugs are being developed by Antisoma and F. Hoffmann-La Roche Ltd.; Antisoma paid $300,000 up front and will pay up to $1.5M in milestones to Inverness, which relinquished its royalty rights; Antisoma's royalty potential increased to 2.66% and 1.5%, respectively (4/21)

Arachnova Therapeutics Ltd.* (UK)

Mitsubishi Pharma Corp. (Japan)

License deal giving Arachnova rights to use MCI-225 in pain, stress urinary incontinence and functional bowel disorder

Mitsubishi had taken the compound to Phase II in depression; Arachnova found the new uses, and gets access to Mitsubishi data under undisclosed terms (3/16)

Arachnova Therapeutics Ltd.* (UK)

Sosei Co. Ltd. (Japan)

Licensing deal involving the new therapeutic use of AA10020/SOU001 for stress urinary incontinence

Sosei is paying up-front fees and potential milestones and royalties in exchange for exclusive worldwide rights; Arachnova's computational prediction technology helped establish the drug's new use (2/25)

ArQule Inc. (ARQL)

Roche Holdings Ltd. (Switzerland)

Partnership to discover and develop drugs targeting the E2F pathway in order to selectively kill cancer cells

Roche is paying $15M up front and providing development support; ArQule will take drugs to Phase II, when Roche could option them for a fee; ArQule could receive up to $276 million for a successful product, as well as royalties, and has a co-promotion option for the U.S. (4/2)

Array BioPharma Inc. (ARRY)

Takeda Chemical Industries Ltd. (Japan)

Collaboration to create a series of small-molecule drug leads against a Takeda target

Array will receive fees for research work and is entitled to milestone and royalty payments; the deal is in addition to their collaboration that began in 2001 (4/5)

Astex Technology Ltd.* (UK)

Boehringer Ingelheim GmbH (Germany)

Three-year, multitarget alliance covering various indications; the deal combines Astex's fragment- based discovery with BI targets

BI will make an up-front payment to Astex and will fund research, as well as make milestone and royalty payments as earned, in exchange for worldwide rights (3/9)

Atrix Laboratories Inc. (ATRX)

Aventis SA (France)

Limited feasibility deal to study two Aventis compounds formulated in Atrix's Atrigel delivery technology

Details on the deal and the therapeutic areas of focus were not disclosed (3/16)

Attenuon LLC*

Kirin Brewery Co. Ltd. (Japan)

Collaboration to develop fully human monoclonal antibodies for therapeutic and diagnostic applications in oncology

Attenuon will receive research funding, while rights to resulting products will be shared; each company maintains owner- ship of its technology (2/24)

Auxilium Pharmaceuticals Inc.*

Ipsen SA (France)

Ipsen gained marketing rights to Testim testosterone gel everywhere but North America and Japan

Auxilium is entitled to milestone and royalty payments; specific terms were not disclosed (4/6)

Biotie Therapies Corp.* (Finland)

Aventis SA (France)

Research and option agreement for joint development of a product to prevent and treat blood-coagulation disorders

Biotie is getting $8.8M in license and milestone fees over 12 months in exchange for Aventis getting exclusive rights to negotiate a license agreement for the bioheparin product (3/9)

BioVision AG* (Germany)

F. Hoffmann-La Roche Ltd. (Switzerland)

Roche got a nonexclusive license to BioVision's Differential Peptide Display technology

The technology allows for visualizing the peptides and small proteins within a sample and to analyze changes; terms of the deal were not disclosed (3/3)

Cengent Therapeutics Inc.*

Novartis Pharma AG (Switzerland)

Cengent will screen for drug candidates against multiple Novartis targets

Cengent will get undisclosed up-front and milestone payments; Cengent will use its Genes To Leads technology in the deal (4/12)

ChemoCentryx Inc.*

Forest Laboratories Inc.

Collaboration to develop small- molecule therapeutics for auto- immune and inflammatory diseases; the focus is on the CCR1 chemokine receptor

Forest gets a license to ChemoCentryx drugs in exchange for cash and equity payments up front; Forest will fund the work for three years, and make research, milestone and royalty payments; ChemoCentryx has co- promotion options (3/15)

Commonwealth Biotechnologies Inc. (CBTE)

DynPort Vaccine Co. LLC

Two-year deal in which they will work together to compete for biodefense vaccine development funding

The companies already are working on three projects together (3/30)

Corixa Corp. (CRXA)

Aventis SA (France)

Aventis Pasteur gets coexclusive and nonexclusive worldwide rights to Corixa's RC-529 adjuvant in multiple diseases

Corixa gets up-front license fees and success-based milestones and royalties; Aventis committed to annual orders for the product, and later could add additional nonexclusive vaccine fields (3/30)

Corixa Corp. (CRXA)

Abbott Laboratories

Abbott got nonexclusive rights to Corixa's TcF antigen for use in an assay to detect antibodies to Trypanosoma cruzi

It is the sixth license deal between the companies; all involve up-front fees and potential milestones and/or royalties (3/2)

Cougar Biotechnology Inc.*

BTG plc (UK)

Cougar gained worldwide rights to abiraterone acetate, a drug being developed for advanced prostate cancer

BTG gets an up-front payment and potential milestones and royalties; terms were not disclosed (4/20)

Cyprotex plc (UK; LSE:CRX)

Solvay SA (Belgium)

Cyprotex will screen compounds for Solvay and provide information on ADME properties

Cyprotex will use its Cloe Screen technology in the deal, terms of which were not disclosed (2/19)

DeCode Genetics Inc. (Iceland; DCGN)

Merck & Co. Inc.

Seven-year alliance under which DeCode will use its genetics and genomics technologies to complement Merck clinical trials

Merck purchased $10M of DeCode stock at $14.50 per share and has a warrant to buy up to $50M more stock at $29 per share over five years; DeCode gets a technology- access fee and potential milestones and royalties; they also may pursue development of pharmacogenomic tests (2/26)

Eidogen Inc.*

Boehringer International GmbH (Germany)

BI got a pilot license to Eidogen's Target Informatics Platform software

The product is a structural informatics enterprise software solution; terms were not disclosed (3/30)

Evotec OAI AG (Germany; FSE:EVT)

Fujisawa Pharmaceutical Co. Ltd. (Japan)

Evotec will identify, synthesize and optimize compounds that show activity against one of Fujisawa's drug targets

Evotec will receive fees for services and potential milestone payments; specific terms and targets were not disclosed (4/13)

Evotec Neurosciences GmbH (subsidiary of Evotec OAI AG; Germany; FSE:EVT)

F. Hoffmann-La Roche Ltd. (Switzerland)

Evotec acquired an exclusive worldwide license to patents covering NMDA receptor NR2B subtype selective antagonists for treating CNS disorders

Roche retained the right to reacquire the compounds, which are in preclinical development; terms of the deal were not disclosed (3/25)

Gastrotech Pharma A/S* (Denmark)

Eli Lilly and Co.

Companies entered deal to continue developing peptides for irritable bowel syndrome and functional dyspepsia

Lilly will manufacture the glucagon-like peptide-1 analogue that is in Phase II trials in IBS, and has an option to further develop and commercialize the product in exchange for milestone and royalty payments (3/31)

Genzyme Corp. (GENZ)

Procter & Gamble Pharmaceuticals Inc.

P&G got an exclusive world- wide license to RDP58 for gastrointestinal and other disorders

Genzyme gets $10M up front and potential milestone payments; Genzyme got the drug through its acquisition of SangStat Medical Corp. in September 2003 (4/1)

Gloucester Pharmaceuticals Inc.*

Fujisawa Pharmaceutical Co. Ltd. (Japan)

Gloucester acquired exclusive worldwide rights to the deacetylase inhibitor FK228 as a cancer agent

Fujisawa receives an up-front license fee and potential milestone payments and royalties; the product is in Phase II trials in two cancer indications (4/15)

GTx Inc. (GTXI)

Ortho Biotech Products LP (Johnson & Johnson)

Collaboration and license deal covering andarine, GTx's lead selective androgen receptor modulator, and certain backup SARM compounds

GTx will receive an up-front licensing fee, additional licensing fees and milestone payments up to $82 million for andarine and up to $45 million for each additional licensed compound; J&J gets a worldwide exclusive license and will take over further development; GTx has U.S. co-promotion options in men's health areas, and would get double-digit royalties (3/17)

Indevus Pharmaceuticals Inc. (IDEV)

Pliva d.d. (Croatia)

Deal giving Pliva subsidiary Odyssey Pharmaceuticals Inc. U.S. rights to Sanctura, a product for overactive bladder that is under FDA review

Indevus gets $30M up front and would get $120M upon FDA approval; it also could earn another $65M in longer-term milestones; Indevus will create a sales force to co-promote the product (4/7)

Ingenium Pharmaceuticals AG* (Germany)

Merck & Co. Inc.

Ingenium will provide Merck genetic rat models with alterations in a gene specified by Merck

Further details of the deal were not disclosed (4/1)

Inpharmatica Ltd.* (UK)

Taisho Pharmaceuticals Co. Ltd. (Japan)

Taisho subscribed to the online Biopendium product containing sequence data

Terms of the deal were not disclosed (3/29)

Inpharmatica Ltd.* (UK)

GlaxoSmithKline plc (UK)

Inpharmatica will apply its in silico ADME technology to undisclosed GSK discovery programs

Terms of the deal were not disclosed (3/22)

InterMune Inc. (ITMN)

Baxter Healthcare Corp.

Deal for InterMune to co- promote Aralast to pulmonologists in the United States

InterMune will detail the alpha-1 proteinase inhibitor for the treatment of hereditary emphysema; terms were not disclosed (3/29)

Kereos Inc.*

Bristol-Myers Squibb Co.

Agreement to develop and sell molecular imaging agents based on Kereos technology

BMS got exclusive rights to cardiovascular agents and Kereos got rights to use BMS targeting molecules for cancer imaging agents and targeted therapeutics; terms were not disclosed (3/2)

LifeCycle Pharma A/S* (Denmark)

Recordati SpA (Italy)

Deal to develop a modified- release formulation of Recordati's hypertension drug Zanidip

LifeCycle will apply its MeltDose technology to the effort, and also will develop the manufacturing process; it is entitled to undisclosed milestones and royalties (4/1)

MediciNova Inc.*

Kissei Pharmaceutical Co. Ltd. (Japan)

MediciNova obtained exclusive rights outside of Japan to KUR- 246 (MN-221), a compound in Phase II for premature labor

MediciNova is making undisclosed up-front, milestone and royalty payments to Kissei (2/25)

NeoGenesis Pharmaceuticals Inc.*

AstraZeneca plc (UK)

Collaboration under which NeoGenesis will use its discovery technologies to find candidates for selected diseases

NeoGenesis will get undisclosed research funding, R&D milestones and royalties on any sales; specific terms were not disclosed (3/25)

Neose Technologies Inc. (NTEC)

BioGeneriX AG (Germany; unit of Ratiopharm Group)

Deal to use Neose's GlycoPEG-ylation technology to develop a next-generation version of granulocyte-colony stimulating factor

BioGeneriX will fund any clinical development in exchange for rights outside North America and Japan; Neose gets an up-front fee and each company would pay the other royalties from sales in its territory (4/20)

Neurocrine Biosciences Inc. (NBIX)


Neurocrine purchased all of Wyeth's financial interest in indiplon, a late-stage insomnia candidate

Wyeth gets $50m in cash and $45M in Neurocrine stock priced at a 15-day average; Wyeth's rights, gained from a deal with DOV Pharmaceutical Inc., move to Neurocrine, which will see its royalty obligations reduced from 6% to 3.5% (2/26)

NexMed Inc. (NEXM)

Unnamed Japanese company

NexMed will provide contract development services for a topical product to treat a form of herpes

NexMed received up-front funding and is eligible to receive milestone payments (3/31)

NPS Pharmaceuticals Inc. (NPSP)

Nycomed Group (Denmark)

Nycomed gained rights to the osteoporosis drug Preos in Europe

Nycomed is making an equity investment of $25M in NPS, paying up to $25M in regulatory and sales milestones, and paying NPS royalties on sales; it also will conduct Phase IIIb and IV studies in Europe (4/21)

Odyssey Thera Inc.*

F. Hoffmann-La Roche Ltd. (Switzerland)

Deal to profile certain Roche compounds across Odyssey's cell-based assays

The focus is to further characterize mechanism of action and pathway activity; terms were not disclosed (4/8)

OriGene Technologies Inc.*

Genomics Institute of the Novartis Research Foundation

Novartis purchased the True- Clone collection of full-length human cDNA clones

Novartis will use the clones in its high- throughput discovery efforts; terms were not disclosed (3/9)

Ovation Pharmaceuticals Inc.*

Aventis SA (France)

Ovation acquired North American rights to the CNS drugs Sabril (vigabatrin) and Frisium (clobazam)

Ovation paid cash in the deal, terms of which were not disclosed; both products are approved in Canada and Mexico, but not in the U.S. (4/5)

Pharming Group NV (the Netherlands; Euronext:PHARM) and Greece

Laboratorios del Dr. Esteve SA (Spain)

Companies signed letter of intent giving Dr. Esteve rights to recombinant human C1 inhibitor in Spain, Portugal

Pharming can get milestones, royalties and contributions to R&D costs; the deal is expected to be finalized by June 30 (4/19)

PPL Therapeutics plc (LSE:PPH)

Exeter Life Sciences Inc.

PPL sold Exeter its rights to Revivicor Holdings Inc.'s gene- targeting technology in the field of protein production

PPL is receiving $150,000 in the deal under which it is disposing of the asset (2/25)

Protein Mechanics Inc.*

Aventis SA (France)

Agreement to advance the discovery and validation of highly selective, orally available matrix metalloprotease inhibitors

Protein Mechanics will use its predictive simulation technology in the deal, terms of which were not disclosed (3/23)

Proteome Sciences plc (UK; LSE:PRM)

Bayer Pharmaceuticals

Proteome licensed certain biomarkers in Alzheimer's disease

Bayer discovered the markers with the University Cantonal Hospital in Switzerland; terms were not disclosed (3/23)

QRx Pharma Pty. Ltd.* (Australia)

Shire Pharmaceuticals Group plc (UK)

Shire will develop extended- release formulations of QRx's opioid product, Q8003

QRx is nearing Phase III trials of an immediate-release version of the drug; terms were not disclosed (3/24)

SemBioSys Genetics Inc.*

Syngenta SA (Switzerland)

Syngenta gets access to SemBioSys' oil body-based systems for developing biologic products

The deal involves an up-front payment to SemBioSys and potential option-exercise fees, milestones and royalties (2/24)

SkyePharma plc (UK;SKYE)

Medeus Pharma Ltd. (UK)

Deal under which Medeus will market DepoMorphine in Europe; a marketing application has been filed for the drug, a morphine formulation

SkyePharma stands to get 35% to 50% of sales, and milestone payments up to $120M; Medeus will pay for manufacturing and sales and be responsible for attaining approvals throughout the EU (4/5)

Solvo Biotechnology Inc.* (Hungary)

MDS Pharma Services (unit of MDS Inc.)

They will provide multidrug- resistance transporter assays for screening and lead optimization and ADME studies

Solvo's ATP-binding cassette transporter protein assays complement MDS's in vitro metabolism services; terms were not disclosed (4/14)

SuperGenInc. (SUPG)

Pfizer Inc.

SuperGen acquired European rights to the cancer drug Nipent, which it already sells in the U.S.

The drug is approved for hairy-cell leukemia and is being studied in a number of hematologic malignancies; terms were not disclosed (2/24)

Theravance Inc.*

GlaxoSmithKline plc (UK)

Broadened deal covering a variety of therapeutic areas; GSK has an option for all current and future programs through August 2007

Theravance gets $129M up front, much of which increases GSK's stake to 19% from 6%; Theravance is eligible for milestones of $162M to $240M per program; the deal also includes a put/call arrangement under which GSK's stake could increase up to 60% in 2007 (3/31)

ThromboGenics Ltd.* (Ireland)

Geymonat SpA (Italy)

Agreement for co-development of placental growth factor, an angiogenesis agent to which each firm has certain rights

The goal of the joint effort is to bring the product into the clinic, and then attract a partner; specific terms were not disclosed (3/3)

Unigene Laboratories Inc. (OTC BB:UGNE)

Novartis Pharma AG (Switzerland)

Novartis gained rights to produce recombinant calcitonin under Unigene's manufacturing process

Unigene will sell calcitonin to Novartis to support Novartis' development programs, while remaining free to develop its own products; Unigene gets $5.6M up front and up to $18.7M in the deal, as well as potential royalties (4/8)

Vela Pharmaceuticals Inc.*

Otsuka Pharmaceutical Co. Ltd. (Japan)

Vela gained rights in the U.S. and Europe for a Phase II compound to treat depression

VelaPharm designated the drug VPI- 013 and plans a Phase II trial in June; terms of the deal were not disclosed (4/1)

Vernalis plc (UK; VNLS)

Elan Corp. plc (Ireland)

Vernalis is reacquiring all North American rights to frovatriptan

Vernalis is paying $50M to Elan through 2005; it plans to find a new partner for the product, which is approved for treating migraine (3/30)

Vion Pharmaceuticals Inc. (VION)

Johnson & Johnson Consumer Companies Inc.

J&J got a worldwide, non-exclusive license to Vion's Melasyn, a synthetic form of melanin

No up-front or milestone payments were included in the deal, but Vion would get royalties on any resulting sales where it holds patent rights (3/15)

Xechem International Inc. (OTC BB:XKEM)

Alembic Ltd. (India)

Agreement to bring Nicosan/ Hemoxin to market for treating sickle cell disease

Alembic is providing Xechem $3.6M; Alembic is entitled to royalties, gained a 15% stake in Xechem's Nigerian subsidiary, and has first refusal rights to distribute the product in India and Africa (4/5)

ZymoGenetics Inc. (ZGEN)

Novo Nordisk A/S (Denmark)

Novo licensed exclusive North American rights to ZymoGenetics' patents covering interleukin-20

Novo is paying $4M up front and would make milestone and royalty payments as warranted; Novo licensed IL-20 rights for the rest of the world in 2001 (3/16)


# The information in the chart does not cover agricultural agreements or those between biotech companies.

* Private companies are indicated with an asterisk.

Unless otherwise noted, stock symbols listed are on the Nasdaq market.

FSE = Frankfurt Stock Exchange; LSE = London Stock Exchange; OTC BB = Over-the-Counter Bulletin Board; TSE = Toronto Stock Exchange.